(A)


Annexin V luminescence (×10⁵ RLU)
0
1
2
3
0
6
12
18
24
Time after treatment (h)
6 μM AU-15330
12 μM AU-15330
18 μM AU-15330
1 μM Staurosporine

(B)


Annexin V luminescence (×10⁵ RLU)
0
1
2
3
***
0 1 3 6 12 15 18 24 0 1 3 6 12 15 18 24 0 1 3 6 12 15 18 24 0 1 3 6 12 15 18 24 (h)
6 μM AU-15330
12 μM AU-15330
18 μM AU-15330
1 μM Staurosporine

(A)


n.s.
n.s.
n.s.
1
0.75
0.50
0.25
0
Relative body weight
(Day0 = 1.00)
Vehicle
AU-15330
0
7
14
21
Days after treatment

(B)


Liver
Lung
Heart
Kidney
Vehicle
AU-15330

(A)


RPL30 exon 3
ChIP signal (% input)
1.5
1.0
0.5
0
Histone H3
IgG
Histone H3
IgG
DMSO
AU-15330

(B)


IgG ChIP signal (% input)
0.03
0.02
0.01
0.00
DMSO
AU-15330
P1
P2
P3

Figure S4


(A)
DMSO
12 μM AU-15330
24 μM AU-15330
36 μM AU-15330
1.9 %
5.0 %
3.4 %
3.1 %
18.8 %
39.3 %
3.0 %
40.2 %
24.5 %
2.7 %
39.0 %
34.0 %
7AAD
PE-Annexin V
(B)
Total apoptotic cells (%)
DMSO
12
24
36
AU-15330 (μM)
***
(C)
DMSO
AU-15330
0
24
48
(h)
PARP
Cleaved-PARP
β-Actin
(D)
Relative PLAU mRNA expression
DMSO
AU-15330
control
Control
3
6
12
Time after treatment (h)
(E)
uPA concentration in culture supernatant (pg/mL)
DMSO
AU-15330
control
Control
3
6
12
Time after treatment (h)

(A)



(B)



(C)



(D)



Control vector : IC_{50} = 15.8 μM
PLAU OE : IC_{50} = 22.0 μM